Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 1, 2008, Pages 157-165

  Shin, Sang Joon ^a   Jeung, Hei Cheul ^a   Ahn, Joong Bae ^a   Choi, Hye Jin ^a   Cho, Byoung Chul ^a   Rha, Sun Young ^a   Yoo, Nae Choon ^a   Roh, Jae Kyung ^a   Chung, Hyun Cheol ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Capecitabine; Doxorubicin; MDR1 gene; Polymorphism; Salvage regimen; Stomach cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; RASH; SALVAGE THERAPY; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; SALVAGE THERAPY; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 34848825963     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0470-3     Document Type: Article

References (22)

1. Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56:1-9
2. Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, Fleig WE (2005) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev:CD004064
3. Wilson D, Hiller L, Geh JI (2005) Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 17:81-90
4. Peter WTP, David PK, Steven MP, Joel ET (2005) Cancer of the stomach. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 7th edn. Lippincott, Williams & Wilkins, Philadelphia, pp 909-939
5. Brugarolas A, Garcia-Moran M, Lacave AJ (1975) Chemotherapy in advanced gastric cancer: a controlled clinical study (abstract). Proc Am Assoc Cancer Res 16:169
6. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY (2004) A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 15:1344-1347
7. Park YH, Ryoo BY, Choi SJ, Kim HT (2004) A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 90:1329-1333
8. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281
9. Stouch TR, Gudmundsson O (2002) Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev 54:315-328
10. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA (2006) Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24:3789-3798
11. Sohn JW, Lee SY, Lee SJ, Kim EJ, Cha SI, Kim CH, Lee JT, Jung TH, Park JY (2006) MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 36:137-141
12. Atalay C, Deliloglu Gurhan I, Irkkan C, Gunduz U (2006) Multidrug resistance in locally advanced breast cancer. Tumour Biol 27:309-318
13. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C (2006) mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12:854-859
14. Miyamoto K, Yoshida S, Saito D, Shimada Y, Tajiri H, Yamaguchi H, Ohkura H, Yoshino M, Yoshida T, Okazaki N (1990) Pilot phase II study of cis-diamminedichloroplatinum (II) against metastatic gastric cancers. Jpn J Clin Oncol 20:169-176
15. Lacave AJ, Izarzugaza I, Anton Aparicio LM, Valle Pereda M, Gracia Marco JM, Buesa JM (1983) Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer. Am J Clin Oncol 6:35-38
16. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalano G (1998) Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 9:307-310
17. Graziano F, Catalano V, Baldelli AM, Giordani P, Testa E, Lai V, Catalano G, Battelli N, Cascinu S (2000) A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 11:1263-1266
18. Shin SJ, Kim MK, Lee KH, Hyun MS, Bae SH, Ryoo HM (2004) The Efficacy of docetaxel and cisplatin combination chemotherapy for the treatment of advanced gastric cancer after failing to 5-FU based chemotherapy: a single-center phase ii study. Cancer Res Treat 36:367-371
19. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, Choi IJ, Ryu KW, Kim YW, Bae JM (2004) Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol 34:8-13
20. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319-323
21. Giuliani F, Molica S, Maiello E, Battaglia C, Gebbia V, Di Bisceglie M, Vinciarelli G, Gebbia N, Colucci G (2005) Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106) Am J Clin Oncol 28:581-585
22. Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Park K (2005) Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br J Cancer 92:1850-1854